

Long Term Outcomes in CDH: Cardiopulmonary Outcomes and Health Related Quality of Life

Leonie Lewis¹, Ian Sinha², Sok-Leng Kang³, Joyce Lim³ and Paul D Losty⁴

¹ Women's And Children's Health, University of Liverpool School of Medicine, UK

² Department Of Respiratory Medicine , Alder Hey Children's Hospital NHS Foundation Trust

³ Department Of Paediatric Cardiology , Alder Hey Children's Hospital NHS Foundation Trust

⁴ Institute Of Life Course And Medical Sciences, University Of Liverpool, UK

Corresponding author:

Leonie Lewis

Department of Women's and Children's Health

University of Liverpool, UK

Email: hlllewis@liverpool.ac.uk

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The authors have no competing interests to declare. Data is available on request from the corresponding author.

Abstract

Background: With improvements in clinical management and an increase in CDH survivorship there is a crucial need for better understanding of long-term health outcomes in CDH.

Aim: To investigate the prevalence of cardiopulmonary health morbidity and health related quality of life (HRQoL) in CDH survivors.

Methods: We included all studies (n=65) investigating long-term cardiopulmonary outcomes in CDH patients over 2 years published in the last 30 years. The Newcastle-Ottawa Scale and the CASP checklist for cohort studies were utilised to assess study quality. Results were reported descriptively and collated by age group where possible.

Results: The incidence of pulmonary hypertension was highly variable (4.5-38%), though rates (%) appeared to diminish after 5 years of age. Lung function indices and radiological outcomes were frequently abnormal, and Health Related Quality of Life (HRQoL) reduced also. Long term diseases notably emphysema and COPD are not yet fully described in the contemporary literature.

Conclusion: This study underscores cardiopulmonary health morbidity and a reduced HRQoL amongst CDH survivors. Where not already available dedicated multidisciplinary follow-up clinics should be established to support these vulnerable patients transition safely into adulthood. Future research is therefore needed to investigate the risk factors for cardiopulmonary ill health and morbidity in CDH survivors.

Introduction

In congenital diaphragmatic hernia (CDH) failure of diaphragmatic closure in utero leads to herniation of abdominal contents into the thoracic cavity. This rare disease occurs in 1 in 3000 births¹, with a current mortality rate of 30%-50%²⁻⁴. Improvements in clinical management over the past two decades have led to an increase in the number of CDH survivors. Infants that do survive to hospital discharge may be left with complex problems affecting many aspects of Health-Related Quality of Life (HRQoL). These significant complications may affect the cardiopulmonary, neurological, or gastrointestinal systems. It is well reported that CDH is linked with developmental insults that induce lung hypoplasia and pulmonary hypertension^{5 6}, and is also associated with extrapulmonary cardiac anomalies⁷⁻⁹. There is, however, less research investigating long-term complications in childhood and adulthood caused by CDH. This is important to understand, so that families of CDH survivors may take appropriate measures to better recognise these and/or prevent adverse sequelae. Healthcare professionals should be increasingly mindful of CDH co-morbidities, and follow-up programmes in certain 'high volume' speciality centres do seek to incorporate elements of multispecialty care.

To the best of our knowledge, there are however currently no systematic reviews focusing specifically on long-term cardiopulmonary outcomes in CDH. We therefore aimed to study and comprehensively appraise the true prevalence of long-term cardiopulmonary outcomes in CDH survivors over 2 years of age.

Aims

- 1) To investigate the prevalence of adverse cardiopulmonary outcomes in survivors with CDH over 2 years of age.
- 2) To determine risk factors for cardiopulmonary morbidity and poor HRQoL in CDH survivors.

Methods

The systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance¹⁰. A PROSPERO protocol (CRD42021254998) was developed and published which defined - (I) study objectives, (II) search strategy, (III) assessment of study quality, (IV) data extraction and (V) analysis.

Search strategy

We searched Pubmed and SCOPUS, a platform for searching multiple databases, using the search '(congenital diaphragmatic hernia OR CDH) AND (Outcome* OR Sequelae OR follow-up OR long-term OR survivors) AND (Cardio* OR Pulmonary OR Respiratory OR Exercise OR Quality of life)'. CENTRAL was also searched using the heading term 'congenital diaphragmatic hernia'. Databases were last searched on 14/05/2021.

We examined all potential studies based on title and abstract. The selected studies were then read in full to screen for eligibility.

Studies were included in the systematic review if they were published in the last 30 years and specifically investigated long term cardiopulmonary outcomes in CDH patients aged over 2 years. We included all cohort studies of those patients with pulmonary hypertension (diagnosed clinically, or by electrocardiogram, or echocardiogram) or having extracorporeal membrane oxygenation (ECMO) where CDH patients were specifically herein evaluated as a distinct group.

We excluded studies of non-English language publications.

Data extraction, quality assessment and data synthesis

Data from the selected eligible studies were extracted by the study authors. Extracted data here included study characteristics and results.

From each study we scrutinized the following characteristics: (a) study design, (b) single or multi-centre study, (c) country of origin, (d) number of patients, and (e) age of patients.

The study results were related to:

- (i) Prevalence of adverse cardiopulmonary outcomes in CDH
- (ii) Risk factors for adverse cardiopulmonary outcomes and HRQoL in CDH

Adverse cardiopulmonary outcomes

(a) Indices of lung function

Basic spirometry is often used by clinicians, but more complex areas of physiologic lung function include plethysmography and exhaled nitric oxide. We extracted absolute measurements e.g. litres or % predicted values, and Z scores (which are a marker of results in comparison to the normal healthy population).

- **Forced Expiratory Volume in the first second (FEV1)** - this is considered a measure of the size of the airways
- **Forced vital capacity (FVC)** - this is a marker of overall lung capacity
- **FEV1/FVC ratio** - this is a marker of airway obstruction
- **Full body plethysmography** - this is a test only used in specialist tertiary centres as a way of evaluating alveolar volume and total lung volume
- **Exhaled nitric oxide** – a marker of airway inflammation

(b) Pulmonary hypertension (PHT)

There are various direct and indirect methods of establishing a diagnosis of PHT. This may be clinical by ECG monitoring (however this is non-specific), by echocardiography (which is non-invasive), and cardiac catheterisation (an invasive technique undertaken in select patients under general anaesthesia). Right ventricular function gives a reproducible indication of the 'work over time' of the right ventricle distributing blood to the pulmonary vasculature.

- **Prevalence of PHT** - either by echocardiogram (Tricuspid Regurgitation >2.8m/s), direct catheter pressure (mean pulmonary artery pressure >25mmHg), or ECG)

If PHT was present we then looked specifically at:

- **Severity of PHT** - mild/moderate/severe (by echocardiogram or catheter)
- **Right Ventricle function** – normal or mild/ moderate/ severe impairment
- **Use of PHT medications**
- **Death related to pulmonary hypertension**

(c) Risk of asthma, emphysema and chronic obstructive pulmonary disease (COPD)

(d) Functional outcomes

- **Exercise tolerance and breathlessness** – including a 6-minute walk test or a cardiopulmonary exercise test
- **Health Related Quality of life (HRQoL)**

(e) Radiological outcomes

- **Chronic visible changes identified on Chest X-ray, CT scan or MRI**

Study quality

The authors assessed study quality based primarily on study design and whether the recruitment of the participants was considered adequate. The Newcastle-Ottawa Scale ¹¹ was then used to quality assess case-control studies, evaluating studies on their selection, comparability, and exposure of the cases and controls. Cohort studies were quality assessed using the CASP checklist for cohort studies ¹². This well-known quality appraisal tool evaluates study quality based on the validity and applicability of their results. Checklist criteria are shown in Supplementary Table E1. Any studies with a high risk of bias were excluded.

Result analysis

Results are reported descriptively and where possible we made effort to collate results by different age groups (2-4, 5-12, 13-18, over 18 years).

Results

Study search and selection

The search of PubMed yielded 838 results, Scopus yielded 928, CENTRAL yielded 168 papers, and 7 were found from additional sources, totalling 1941 papers. After removal of 507 duplicates, 1434 papers were further screened. Titles and abstracts were assessed in full for eligibility, excluding 1332 papers. The remaining 102 publications were independently read in full and a further 37 papers excluded, see **Supplementary Table E2** – ‘reasons for exclusion’.

65 papers were finally included, 22 case control studies in the main analysis, as the best levels of evidence currently available. A further 43 cohort studies were included in the additional analysis. **Figure 1** shows the PRISMA flowchart for the study.

Study characteristics

There were 65 studies, which overall included 3061 CDH patients. The mean number of CDH patients were 47 per publication (range 7-251). All studies were observational (22 case control and 43 cohort). 54 were single-centre studies and 11 were multi-centre. Studies were conducted in various countries including those in the UK, Europe, USA, Canada, Asia, Africa, and Australia. CDH patient age ranged from 0-42 years, though the mean or median age in each selected study was above 2 years.

Study Quality

Case control study quality (assessed using the Newcastle Ottawa Scale¹¹) is shown in **Supplementary Table E3**. Cohort study quality (assessed using the CASP checklist for cohort studies¹²) is available in **Supplementary Table E4**.

Study quality was considered adequate. Outcomes were often measured accurately, papers investigating spirometry data almost always followed the American Thoracic Society (ATS) or European Respiratory Society (ERS) guidelines, and the majority of papers investigating pulmonary hypertension deployed echocardiography as sole means of determining PHT. However, very few papers here reported results with corresponding confidence intervals. 20/64 (31%) studies were retrospective rather than prospective. Retrospective studies are notably less likely to have predetermined objectives and standardised outcomes and are therefore more susceptible to having confounding variables. Not all relevant confounding factors were considered in these papers. Many papers identified gestational age as a confounding factor, but not for example the exposure of CDH patients to 'second-hand smoke', family history of cardiorespiratory disease, or socioeconomic/deprivation factors.

Study results

Indices of lung function

Spirometry results - FEV1, FVC, and FEV1/FVC ratio

Spirometry results are shown in **Table 1**. Outcomes were reported in various different ways, as raw values, % predicted, Z score, and standard deviation score. Heterogeneity observed here limited the comparisons we could make between the spirometry results.

Spirometry results in CDH cases vs healthy controls

Seven papers compared spirometry results between CDH patients and healthy controls ¹³⁻¹⁹.

5 studies had a mean participant age of between 5 and 12 years (children) and found FEV1 to be reduced in CDH vs controls in 4/5 studies ^{13 14 16 18}, FVC in 3/5 studies ²⁶⁴^{14 18} and FEV1/FVC in 2/3 studies ^{16 18} ($p < 0.05$).

A single paper ¹⁵ had a mean participant age range of 13 - 18 years (adolescents) and found FVC, FEV1, and FEV1/FVC to be all significantly reduced in CDH vs controls ($p < 0.05$).

A further paper ¹⁹ noted FEV1/FVC to be statistically significantly reduced ($p < 0.05$) in adults with CDH vs controls (mean standard deviation score [SDS] (mean) -0.8 (1.2) vs 0.0 (1.0) $p = 0.008$). FEV1 (mean SDS (SD) -1.2 (1.4) vs -0.2 (1.5) $p = 0.071$) and FVC (mean SDS (SD) -0.7 (1.1) vs -0.3 (1.3) $p = 0.243$) were not statistically significantly different between CDH survivors and controls.

Full body plethysmography

Ijsselstijn *et al* ²⁰ reported CDH patients to have significantly higher residual volumes and residual volume/total lung capacity vs. control patients ($p = 0.001$ and 0.006) at a mean age of 11.7 (range 7-18) years.

Laviola *et al* ²¹ found tidal volume was significantly lower in CDH patients compared to healthy controls ($p < 0.05$) both in those with prosthetic patch and native primary diaphragm repair. This was however not the case when tidal volume was then normalised to body weight. Air trapping was not significantly different between CDH vs. controls.

Spoel *et al*¹⁹ found that TLC, Residual Volume (RV), and Functional Residual Capacity (FRC) were not significantly different in CDH vs controls (p=0.977, p=0.071 and p=0.960 respectively). Spoel *et al*²² reported mean standard deviation (SD) scores for total lung capacity (TLC) to be 0.21 (1.61), and RV%TLC - 25.3 (4.48). This was not compared to any control group(s).

Spoel *et al*¹⁷ showed that 12/14 (86%) CDH patients had a significant volume of air trapping (FRC plethysmography / spirometry >1.10) on body plethysmography at age(s) 8 and 12 years.

Exhaled nitric oxide

Gischler *et al*²³ reported the median fraction of exhaled Nitric Oxide (FENO) in CDH patients to be in the low range of normative values (median 5.2 (range, 2.8-10.0)).

Risk factors for reduced indices of lung function

Factors associated with reduced PFTs included:

(i) Diaphragm defect size - CDH International Study Group Grading – notably here ‘severe’

Grades C and D ²⁴

(ii) Smaller patient head size or abdominal circumference at birth ¹³

(iii) A lower BMI ²⁵

(iv) Gastro-oesophageal reflux disease ¹⁸

(v) Duration of ventilation ^{18 20 26}

(vi) Oxygen use at hospital discharge ²⁴

(vii) Lower total lung volume(s) ¹³

(ix) Ventilated volume of the ipsilateral lung to the diaphragmatic defect ²²

Factors not proven to be significantly associated with reduced PFTs:

(a) Patients with a sedentary vs active lifestyle ^{27 28}

(b) Gestational age ²⁰

(c) Birth weight ²⁰

(d) Parental smoking ²⁰

(e) Neonatal factors including highest peak inspiratory pressure(s), highest partial pressure of carbon dioxide (paCo₂), APGAR score(s) at 5 mins¹⁵ and maximum fraction inspired oxygen (FiO₂)²⁰

(f) ECMO use²⁴

(g) Left-sided CDH defect²⁴

(h) Respiratory muscle training²⁹

(i) Primary vs patch diaphragm repair³⁰

Pulmonary hypertension

Thirteen studies^{16 26 27 31-40} investigated pulmonary hypertension in CDH survivors. Five of which were case control studies^{16 27 31-33}, six retrospective cohort studies^{34-37 39 40}, and two prospective cohort studies^{26 38}. Patient age ranged from 4 months - 26 years.

Prevalence of Pulmonary hypertension

Eleven studies investigated the prevalence of pulmonary hypertension in CDH. Five studies had a mean or median participant age of between 2-5 years (pre-school), five papers had a mean or median participant age range of between 5-13 years (children), one paper reported on PHT in both pre-schoolers and children. No papers focused exclusively on adolescents or adult survivors with PHT. No publications focused on the natural history of pulmonary vascular pressures over time in patients with CDH.

Pulmonary hypertension in pre-schoolers with CDH

Six papers reported prevalence of PHT in participants with CDH where the average age was between 2 and 5 years (preschool). All six papers used echocardiography to diagnose PHT. Rates of pulmonary hypertension ranged here from 4.5% to 38%^{33 34 36-38 40}.

Pulmonary hypertension in children with CDH

Six papers investigated prevalence of PHT in children with CDH. Four studies again used exclusively echocardiography for diagnosis^{16 26 27 32}, one study used both echocardiogram and ECG³¹, and a single study did not specify their exact mode of diagnosis for PHT³⁶. No studies with an average participant age group of over 5 years reported any incidence (%) of PHT, despite a single study recording 33% of CDH newborns having PHT²⁷ and another study reporting that some 5.1% of preschool aged children had PHT³⁶.

Pulmonary hypertension in adolescents and adults with CDH

Strikingly, there were no reports evident of PHT recorded in adolescents or adults with CDH.

Severity of Pulmonary hypertension

A single manuscript documented PHT as 'severe' in two preschool aged children with CDH, though the study authors did not provide a clear definition with regard to severity³⁷.

Right ventricle function

Pulmonary hypertension can result in varying severity and degrees of right ventricle dysfunction. Five studies here sought to investigate right ventricle function.

From Doppler imaging Egan *et al*³² showed a significant reduction in systolic (s') and early diastolic wave (e') velocities in children with CDH, indicating a degree of right ventricle impairment, compared to matched controls ($p < 0.01$ and $p = 0.02$ respectively). Right ventricle strain values were however not significantly different between CDH survivors and controls ($p > 0.05$).

Schwartz *et al*³³ and Van Meurs *et al*³⁸ reported right ventricular hypertrophy and right axis deviation from ECG studies conducted in preschool aged patients. Schwartz *et al* showed that 6/21 (29%) of patients had either right axis deviation or right ventricular hypertrophy, 2 of whom also had PHT. Van Meurs *et al* reported 6/18 (33%) CDH patients having evidence of right ventricular hypertrophy, four here (4/18 22%) also had right axis deviation.

Stefanutti *et al*²⁶ estimated right ventricle systolic pressure (RVsp) in children with CDH (mean age \pm SD, 8.15 years \pm 2.80), and found these values to be apparently normal.

Values ranged from 20 to 30 mmHg (mean SD 24.43 \pm 3.57 mm Hg). These were not compared to systolic blood pressure, but an RVsp of less than 30mmHg was considered normal.

Wong *et al* ³⁹ also deployed echocardiography to monitor right ventricular systolic pressure(s) (RVsp) in preschool aged patients.

Mean RVsp was between 25 and 30 mmHg (read from graph) though again this was not compared to mean systolic blood pressure or left ventricular pressure.

Use of pulmonary hypertension agent medication(s)

Three papers reported pharmacologic use of PHT medications. All three papers here reported that all the CDH study participants with PHT required pulmonary vasodilator therapies, such as sildenafil ^{34 37 40}.

Reports of late death

A single paper ³⁵ reported a late death from pulmonary hypertension in a 9-year-old CDH survivor.

Risk factors for PHT

The only associated factor(s) linked with presence of pulmonary hypertension (defined as raised RVsp) were in those CDH infants defined as 'high risk' index cases. High risk patients were notably those with an Observed/Expected lung to head ratio (O/E LHR) \leq 45%. High risk CDH survivors had persistently higher right ventricular systolic pressures on serial echocardiography at 2-5 years old compared to 'low risk' CDH survivors ($p < 0.05$) ³⁹.

Garcia *et al* ³⁴, however by contrast, found LHR not to be associated with presence of PHT ($p = 0.54$).

A further study by Shieh *et al*⁴⁰ showed that CDH patients who had underwent ex utero intrapartum treatment (EXIT) then onto ECMO support to have higher rates of PHT requiring sildenafil, though this was not statistically significant (0/8 vs 2/9 p=0.16).

Asthma, Emphysema, Chronic Obstructive Pulmonary Disease (COPD)

Asthma

Eight case control papers^{14 16 19 32 41-43} investigated asthma diagnosis, symptoms, or medication use in CDH survivors. Results were very mixed - publications found rates of asthma, symptoms, or medication use to be both significant^{16 19 42 43} and not significant^{16 19 20 43} when compared to aged matched controls. Often the amount of scattered data reported here was too small to draw firm conclusions^{14 32 41}.

14/15 cohort studies that investigated rates of asthma reported asthma (%) or asthma agent medication use in CDH survivors^{23 30 36 40 44-54}. This was found to be closely associated with pulmonary support on day 30 of life, low birthweight, and lower gestational age^{43 46}.

Emphysema and COPD

There were no documented reports of emphysema or COPD in CDH survivors or controls though it is likely that patients here were too young at the point of publication of these studies to fully accurately reflect these factors.

Cardiopulmonary exercise testing (CPET)

Eight studies described using CPET with CDH survivorship follow-up. All four case control studies found CPET to be reduced in CDH survivors compared to controls ($p < 0.05$)^{14 27 55 56}.

A further four cohort studies noted abnormal CPET parameters in CDH patients^{23 28 57 58}.

There were significant differences recorded in CPET between CDH survivors who were considered 'athletic' vs. those who had a 'sedentary' lifestyle ($p < 0.05$)^{27 28 56}. Of interest here CDH survivors often perceived their own levels of fitness to be worse than their healthy counterparts¹⁴.

Risk factors for reduced CPET results

Predictors for worse CPET results were (i) a reduced FEV1⁵⁵, (ii) a higher residual volume/total lung capacity value⁵⁵, (iii) diffusion capacity corrected for alveolar volume (Kco)⁵⁸, (iv) ECMO use⁵⁸ (v) duration of hospital stay⁵⁸, (vi) parent's estimation of their child's exercise capacity⁵⁸, and (vii) those CDH index cases who were considered sedentary rather than athletic^{14 27 56}. Duration of neonatal ventilation support was not found to be significantly associated with CPET results²⁷.

Radiological outcomes

Diaphragm radiology

Diaphragm growth⁵⁹ and markers of diaphragmatic strength were reduced in CDH survivors compared to controls⁶⁰ ($p < 0.05$). Another study found diaphragm mechanical dysfunction to be present in CDH survivors⁶¹.

Chest CT Imaging

Three studies examined and reported Chest CT imaging in CDH survivors, two of which showed abnormalities. These imaging findings included 'subpleural triangular opacities, architectural lung distortion, and linear lung opacities' ¹⁶ as well as 'flat costo-phrenic angles, peripheral opaque spikes of parenchymal consolidation, lung hyperlucency, and mediastinal shift' ²⁶.

Lung perfusion

Three studies described measurement of lung perfusion ^{39 53 62} and found this to be reduced in the ipsilateral lungs of CDH patients. A single study found ipsilateral mean lung density to be reduced also compared to controls ($p=0.0005$) ⁶³. Ventilation/perfusion (V/Q) mismatch or ventilation abnormalities were present in all three CDH studies where fully investigated ^{22 51 63-66}.

Risk factors for abnormal radiology

Markers of abnormal radiology evident in CDH survivors included: (i) those who had a diaphragm patch repair ^{51 53 64} (ii) ECMO or high flow oscillatory ventilation (HFOV) use ^{51 64 66}, (iii) individuals with frequent respiratory tract infections ⁵¹, (iv) index cases with right sided CDH defects ⁵¹, and (v) those on pulmonary support at day 30 of life ⁴⁶. Kamata *et al*, however, found patch repair not to be correlated with abnormal radiology findings ⁵⁹. Wong *et al* reported that lung perfusion did not significantly differ between high and low risk patients ³⁹.

Health Related Quality of Life

Four case control studies reported HRQoL of which, all here found HRQoL to be reduced in CDH survivors compared to healthy matched controls^{16 41 67 68}. Ten cohort studies also examined HRQoL. Six out of ten publications found health related quality of life^{52 69-73} to be considerably reduced in the CDH survivors.

Risk factors for reduced HRQoL

Risk factors significantly associated with reduced HRQoL included (i) oxygen dependence on day 30 of life⁷⁴, (ii) hospital length of stay⁷³, (iii) lack of prenatal diagnosis (%)⁷⁵, (iv) those with ongoing medical morbidities^{68 70} particularly respiratory symptoms^{41 67}, (v) primary diaphragm defect repair,⁶⁹ (vi) supplemental GI feeds⁶⁹ and (vii) neonatal ECMO use⁷².

Thoracoscopic CDH repair was found to be associated with a higher median HRQoL score⁵². Patient age was notably associated with both a better and a worse HRQoL^{52 72}.

Risk factors found not to be significantly associated with a reduced HRQoL included (a) prematurity⁷⁶, (b) prolonged hospital stay⁷⁶, (c) Oxygen requirement at primary hospital discharge⁷⁶, (d) use of neonatal ECMO^{70 74}, (e) cardiac problems⁷⁰, (f) genetic abnormalities⁷⁰, (g) disease severity⁷⁴, and (h) prenatal imaging characteristic values⁷⁴.

Discussion

The primary outcomes of this current study were to investigate the prevalence of cardiopulmonary health outcomes and HRQoL in CDH survivors.

We show that indices of lung function are clearly abnormal in CDH survivors. There was varied quality of reporting here regarding spirometry data. This meant an in-depth analysis into the precise extent of lung function morbidity and its severity was hampered.

Nevertheless, there is evidence that reduced indices of lung function are associated with poorer health outcomes^{77 78}.

The incidence of pulmonary hypertension in CDH survivors was further markedly highly variable due to the non-standardised diagnostic criteria utilised for establishing PHT between individual cohort studies and variances in diagnostic modalities i.e.

ECG/Echocardiogram. Rates (%) of PHT appeared appreciably much higher in preschool aged children than in those CDH survivors over 5 years old indicating the speculative possibility that PHT may diminish in incidence with age. The reduced rates of PHT noted with age could also be due to 'late unrecorded deaths' from PHT, or the fact that reports of late PHT may be more likely to appear in case reports or case series, rather than case control or cohort studies, particularly for example those involving lung transplantation⁷⁹. We found eight recorded cases of late death(s) in those patients <2 years of age, five of which were attributed and linked to respiratory causes^{35 48 49}, one of which was due to persistent pulmonary hypertension³⁵.

Radiological outcomes in CDH survivors were often very abnormal with CPET including HRQoL frequently diminished. Findings regarding asthma diagnosis or medication use showed mixed and varied results from many case-controlled studies, though were well

reported by the cohort studies. There were no definitive reports detailing the diagnosis of emphysema or COPD.

Our secondary outcome was to investigate then risk factors for cardiopulmonary morbidity in CDH survivors. Unfortunately, there was limited data available here. Most notably was the lack of robust data surrounding CDH defect size and poor long-term outcomes, despite some reports detailing a linkage between CDH defect size and its severity⁸⁰. It is clear therefore that further prospective multicentre studies on risk factors for cardiopulmonary health morbidity in CDH survivors are needed. Additional research into other notable long-term health sequelae namely neurological morbidity and failure to thrive in CDH survivors are also required.

At the time of writing this report we do not have enough robust data to show if varying surgical techniques, notably open vs thoracoscopic and primary vs patch repair, have significant differences on long term health outcomes other than diaphragm recurrence or HRQoL. Detailed research into surgical technique and its consequences on hernia recurrence should be a major focus of future ongoing collaborative network studies.

Reduced oxygenation index (OI) has been shown to indicate poor neonatal outcomes and mortality⁸¹. We did not include OI as a pre-specified outcome in this systematic review study, however again further research work into the usefulness of oxygenation index (OI) as a long-term prognostic marker is needed.

In context of the overall findings of this current study it is clear CDH survivors should be followed up in specialist clinics / health care programmes that can readily identify complications. In the multidisciplinary CDH clinic held in Liverpool we regularly monitor children up to adulthood. We are cognizant that there is a crucial window of 'optimal airway growth and lung development' with our CDH patients, during which we routinely test pulmonary function at our lung laboratory. Spirometry is commenced from age 5 years, when children can be better engaged and cooperative with invasive testing^{82 83}. Gas transfer studies and body plethysmography to test for lung volumes are commenced around age 11 years and are undertaken on an individual basis up to adulthood depending on the needs of the child. One limitation we acknowledged from the current study is the small sample (n) size of CDH patients in all the eligible publications we scrutinized, although due to the rare nature of the birth defect itself this is perhaps to be expected. Another limitation, open to debate, is perhaps the inclusion of studies spanning a time period of 30 years. This time period covers an era during which new and emerging care strategies have evolved yielding a wide spectrum of CDH disease morbidity whilst also bringing into sharp focus the ongoing challenges of CDH to all clinicians as an 'unsolved problem' in 2022.

To the best of our knowledge this is the first systematic review study to comprehensively analyse long term cardiopulmonary health outcomes in CDH survivors. Various narrative reviews have made effort to tackle outcomes including asthma, respiratory tract infection(s), bronchopulmonary dysplasia, pulmonary function testing, chest X-ray radiology, health related quality of life (HRQoL) and exercise endurance in CDH.

A single yet crucially important paper has also focused additionally on the impact of CDH to the wider family⁸⁴. These varied and useful published reports share some ideological themes^{6 84-92}.

The requirement for long term after care CDH follow-up has been arguably emphasized before^{5 93}. The current study, however, crucially shows an underscored prevalence of chronic health morbidity in CDH and strikingly what we consider are the real 'unmet needs' of vulnerable at-risk patients and families. There is compelling evidence now for CDH multidisciplinary clinics to be made more widely available in all world healthcare systems.


Conclusion

In summary we show that cardiopulmonary morbidity and a reduced HRQoL are widely prevalent and underscored amongst CDH survivors. Multidisciplinary follow-up should be a 'standard of care' established by clinical teams to support CDH patients and their families transition health needs smoothly into adulthood. Future well designed prospective studies into the risk factors for cardiopulmonary complications, as well as research work addressing other long-term outcomes are vitally needed.

Table 1: Spirometry results in CDH patients before bronchodilator therapy

Study	Age of Patients (years) mean (median) ± SD (range)	Spirometric values /mean ± SD (range)			% predicted /mean ± SD (range)			Z score /mean ± SD (range)			SD score /mean ± SD (range)		
		FEV1	FVC	FEV1/FVC	FEV1	FVC	FEV1/FVC	FEV1	FVC	FEV1/FVC	FEV1	FVC	FEV1/FVC
Children (5-12 years)													
Spael <i>et al</i> ¹⁷	5												
Gischler <i>et al</i> ²³	5				91 (72-122)								
Koh <i>et al</i> ¹³	6.2 ± 0.2	1.1 ± 0.05	1.2 ± 0.1		90.7 ± 2.7	91.2 ± 2.6	91.1 ± 1.3						
Turchetta <i>et al</i> ⁹⁴	6.6 ± 2.6				78.7 ± 19.3	75.5 ± 15							
Spael <i>et al</i> ¹⁷	8												
Majaesic <i>et al</i> ⁹⁵	8				63 ± 18	72 ± 18	80 ± 14						
Stefanutti <i>et al</i> ²⁶	8.15 ± 2.80				89.77 ± 16.33	88.23 ± 16.11	91.10 ± 6.44						
Bojanic <i>et al</i> 2016 ²⁷	8.2 ± 5.7	2.33 ± 1.05	2.66 ± 1.19	0.89 ± 0.09	91.6 ± 20.1	91.2 ± 19.4							
Moawd <i>et al</i> ⁹⁶	(9-11)				72.3 ± 8.5	78.5 ± 9.8							
Tan <i>et al</i> ¹⁶	10 (4-22)							-1.49 ± 1.99	0.26 ± 1.81	-1.92 ± 0.87			
Zaccara <i>et al</i>	11.25 (6-19)				86 ± 13	90 ± 15							
Haliburton <i>et al</i> ²⁵	11.3 ± 3.4							-2.21 ± 1.68	-1.32 ± 1.39	-1.78 ± 0.73			
Marven <i>et al</i> ¹⁴	11.5 (7.3-16.9)				78.7 (72.5-84.8)	84.7 (78.8-90.6)							
Ijsselstijn <i>et al</i> ²⁰	(11.7) (7-18)				89 ± 3		77 ± 2						
Peetsold <i>et al</i> ¹⁸	11.9 ± 3.5							-1.63 ± 1.78 (-7.14-1.45)	-1.28 ± 1.62 (-6.33-1.93)	-0.84 ± 1.27 (-4.03-1.07)			
Spael <i>et al</i> ¹⁷	12												
Spael <i>et al</i> ¹⁹	11.8 ± 2.6												
Adolescents (13-17 years)													
Trachsel <i>et al</i> ¹⁵	13.2 (10.2-16.9)				79 ± 16	85 ± 14	78 ± 10						
Adults (>18 years)													
Peetsold <i>et al</i> ⁵⁷	24.3 ± 4.1							-1.30 ± 1.37	-0.84 ± 1.52	-0.80 ± 1.34			
Spael <i>et al</i> ¹⁹	26.8 ± 2.9												
Spael <i>et al</i> ²²	28.4 (18.1-31.0)												

Figure 2: PRISMA Flowchart



Supplementary Tables

Supplementary Table E1: Quality assessment checklist criteria – Newcastle Ottawa Scale for Case Control studies and CASP Checklist for Cohort studies

Newcastle Ottawa scale for case control studies (one point given for each starred item)	
Selection /4	1) <u>Is the case definition adequate?</u> a) yes, with independent validation ✱ b) yes, e.g. record linkage or based on self-reports c) no description
	2) <u>Representativeness of the cases</u> a) consecutive or obviously representative series of cases ✱ b) potential for selection biases or not stated
	3) <u>Selection of Controls</u> a) community controls ✱ b) hospital controls c) no description
	4) <u>Definition of Controls</u> a) no history of disease (endpoint) ✱ b) no description of source
Comparability /2	1) <u>Comparability of cases and controls on the basis of the design or analysis</u> a) study controls for _____ (Select the most important factor.) ✱
	b) study controls for any additional factor ✱
Exposure /3	1) <u>Ascertainment of exposure</u> a) secure record (e.g. surgical records) ✱ b) structured interview where blind to case/control status ✱ c) interview not blinded to case/control status d) written self report or medical record only e) no description
	2) <u>Same method of ascertainment for cases and controls</u> a) yes ✱ b) no
	3) <u>Non-Response rate</u> a) same rate for both groups ✱ b) non respondents described c) rate different and no designation

CASP critical appraisal tool for cohort studies (Answers given as 'yes', 'can't tell' 'no')	
1. Did the study address a clearly focused issue?	<p>HINT: A question can be 'focused' in terms of:</p> <ul style="list-style-type: none"> • the population studied • the risk factors studied • is it clear whether the study tried to detect a beneficial or harmful effect • the outcomes considered
2. Was the cohort recruited in an acceptable way?	<p>HINT: Look for selection bias which might compromise the generalisability of the findings:</p> <ul style="list-style-type: none"> • was the cohort representative of a defined population • was there something special about the cohort • was everybody included who should have been
3. Was the exposure accurately measured to minimise bias?	<p>HINT: Look for measurement or classification bias:</p> <ul style="list-style-type: none"> • did they use subjective or objective measurements • do the measurements truly reflect what you want them to (have they been validated) • were all the subjects classified into exposure groups using the same procedure
4. Was the outcome accurately measured to minimise bias?	<p>HINT: Look for measurement or classification bias:</p> <ul style="list-style-type: none"> • did they use subjective or objective measurements • do the measurements truly reflect what you want them to (have they been validated) • has a reliable system been established for detecting all the cases (for measuring disease occurrence) • were the measurement methods similar in the different groups • were the subjects and/or the outcome assessor blinded to exposure (does this matter)
5. (a) Have the authors identified all important confounding factors?	<p>HINT: list the ones you think might be important, and ones the author missed</p>
5. (b) Have they taken account of the confounding factors in the design and/or analysis?	<p>HINT: look for restriction in design, and techniques e.g. modelling, stratified-, regression-, or sensitivity analysis to correct, control or adjust for confounding factors</p>

<p>6. (a) Was the follow up of subjects complete enough?</p>	<p>HINT: Consider:</p> <ul style="list-style-type: none"> • the good or bad effects should have had long enough to reveal themselves • the persons that are lost to follow-up may have different outcomes than those available for assessment • in an open or dynamic cohort, was there anything special about the outcome of the people leaving, or the exposure of the people entering the cohort
<p>6. (b) Was the follow up of subjects long enough?</p>	
<p>7. What are the results of this study?</p>	<p>(Included in the results section of our systematic review, rather than the quality assessment results table)</p>
<p>8. How precise are the results?</p>	<p>HINT: look for the range of the confidence intervals, if given</p>
<p>9. Do you believe the results?</p>	<p>HINT: Consider:</p> <ul style="list-style-type: none"> • big effect is hard to ignore • can it be due to bias, chance or confounding • are the design and methods of this study sufficiently flawed to make the results unreliable • Bradford Hills criteria (e.g. time sequence, dose-response gradient, biological plausibility, consistency)
<p>10. Can the results be applied to the local population?</p>	<p>HINT: Consider whether:</p> <ul style="list-style-type: none"> • a cohort study was the appropriate method to answer this question • the subjects covered in this study could be sufficiently different from your population to cause concern • your local setting is likely to differ much from that of the study • you can quantify the local benefits and harms
<p>11. Do the results of this study fit with other available evidence?</p>	
<p>12. Does the study have implications for practice?</p>	<p>HINT: Consider:</p> <ul style="list-style-type: none"> • one observational study rarely provides sufficiently robust evidence to recommend changes to clinical practice or within health policy decision making • for certain questions, observational studies provide the only evidence • recommendations from observational studies are always stronger when supported by other evidence

Supplementary Table E2: Reason for study exclusion

Paper	Reason for exclusion
Arena et al ⁶⁰	Duplicate
Bagolan & Morini et al ⁸⁶	Literature review
Cashen et al ⁹⁷	CDH not analysed as a separate cohort to ECMO patients
Chiu & Hedrick et al ⁹⁸	Literature review
Cortes et al ⁹⁹	Patients too young at follow-up (average age <2 years)
Delacourt et al ⁸⁵	Literature review
Glinianaia et al ¹⁰⁰	Systematic review
Hamutcu et al ¹⁰¹	CDH not analysed as a separate cohort
Hollinger & Buchmiller et al ¹⁰²	Literature review
Hollinger et al ⁸⁴	Literature review
Huddy et al ¹⁰³	No age at follow up
Iguchi et al ¹⁰⁴	CDH not analysed as a separate cohort to ECMO patients
Ijsselstijn & van Heijst et al ⁸⁷	Literature review
Ijsselstijn et al ¹⁰⁵	Literature review
Kassner et al ¹⁰⁶	Incorrect outcomes analysed (not cardiorespiratory)
Kattan ¹⁰⁷	Literature review
Lally & Engle et al ¹⁰⁸	Literature review
Leeuwen & Fitzgerald et al ¹⁰⁹	Literature review
Lund et al ¹¹⁰	Incorrect outcomes analysed (not cardiorespiratory)
Mansell ¹¹¹	Literature review
Matina et al ⁸⁹	Literature review
Matina et al ⁸⁹	Literature review
Morini et al ⁹⁰	Literature review
Mota et al ¹¹²	CDH not analysed as a separate cohort to pulmonary hypertension patients
Mugford et al ¹¹³	Systematic review
Nobuhara et al ¹¹⁴	Incorrect outcomes analysed (not cardiorespiratory) and patients too young at follow-up
Peetsold et al ⁶	Literature review
Prendergast et al ¹¹⁵	Patients too young at follow-up (average age <2 years)
Safavi et al ³⁷	No age at follow up
Suda et al ¹¹⁶	No age at follow up
Van den Hout et al ¹¹⁷	Literature review
van der Cammen-van Zijp et al ¹¹⁸	Duplicate
van der Cammen-van Zijp et al ¹¹⁹	Duplicate
Vanamo et al ¹²⁰	CDH not analysed as a separate cohort
West & Wilson et al ⁹²	Literature review
Zach & Eber et al ¹²¹	Literature review
Zollner et al ¹²²	Incorrect outcomes analysed

Supplementary Table E3: Newcastle-Ottawa study quality scale

Study	Total score /9	Selection /4	Comparability/2	Exposure/3
Abolmaali et al ³¹	7	3	2	2
Arena et al ⁶⁰	5	2	1	2
Bojanic et al 2016 ²⁷	7	3	2	2
Bojanic et al 2018 ⁴¹	6	3	1	2
Egan et al ³²	3	1	1	1
Ijsselstijn et al ²⁰	6	2	2	2
Kamata et al ⁵⁹	4	3	0	1
Koh et al ¹³	5	2	2	1
Koivusalo et al ⁴²	5	2	2	1
Laviola et al ²¹	6	3	1	2
Levesque et al ⁴³	7	4	1	2
Marven et al ¹⁴	6	4	2	0
Michel et al ⁶⁷	7	4	2	1
Peetsold et al ⁷³	7	4	2	1
Poley et al ⁶⁸	3	3	0	0
Schwartz et al ³³	6	3	1	2
Spoel et al ¹⁹	6	2	2	2
Stoll-Dannenhauer et al ⁶³	5	2	1	2
Tan et al ¹⁶	6	3	2	1
Trachsel et al 2005 ¹⁵	8	4	2	2
Trachsel et al ⁵⁵	8	4	2	2
Zaccara ⁵⁶	5	3	1	1

Supplementary Table E4: Quality assessment using CASP checklist for cohort studies¹²

Paper	Clearly focused issue?	Cohort recruited in an acceptable way?	Exposure accurately measured to minimise bias?	Outcome accurately measured to minimise bias?	Identified all confounding factors?	Taken account of confounding factors in design or analysis?	Follow up complete enough?	Follow up long enough?	Are the results precise ?	Do you believe the results?	Can results be applied to local population?	Do the results fit with other available evidence?	Does the study have implications for practice?
Ali et al ⁴⁴	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Amin et al ⁷⁶	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Bojanic et al ⁴⁵	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Cauley et al ⁴⁶	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Chen et al ⁷⁰	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Chiu et al ⁴⁷	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Crankson et al ⁴⁸	Can't tell	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Dao et al ²⁴	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Davis et al ⁴⁹	Can't tell	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Engle et al ⁵⁰	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Ferrante et al ¹²³	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Fritz ⁷¹	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes

Garcia et al ³⁴	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Gischler et al ²³	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Gray et al ¹²⁴	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Haliburton et al ²⁵	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Hayward et al ⁶⁴	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kamata et al ⁵¹	Can't tell	Yes	Yes	Yes	No	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Khirani et al ⁶¹	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
King et al ⁶⁵	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Majaesic et al ⁹⁵	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Mesas Burgos et al ³⁵	Yes	Yes	Yes	Can't tell	No	No	Yes	Yes	N/A	Yes	Yes	Yes	Yes
Moawd et al ⁹⁶	Yes	Yes	Yes	Can't tell	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Morsberger et al ⁵²	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Muratore et al ⁶⁶	Yes	Yes	Yes	Can't tell	No	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Ost et al ⁷²	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Pal & Gupta ⁵³	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Peetsold et al ⁵⁷	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Peetsold et al ¹⁸	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Rocha et al ³⁶	Yes	Yes	Yes	Can't tell	No	No	Yes	Yes	N/A	Yes	Yes	Yes	Yes

Safavi et al ³⁷	Yes	Yes	Yes	Can't tell	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Sheikh et al ₇₄	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Shieh et al ⁴⁰	Yes	Yes	Yes	Yes	No	No	Yes	Yes	N/A	Yes	Yes	Yes	Yes
Spoel et al ¹⁷	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Spoel et al ²²	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Stefanutti et al ₂₆	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Toussaint-Duyster et al ₅₈	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Turchetta et al ⁹⁴	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Valfre et al ³⁰	Yes	Yes	Yes	Can't tell	No	No	Yes	Yes	N/A	Yes	Yes	Yes	Yes
Van Meurs et al ³⁸	Yes	Yes	Yes	Yes	No	No	Yes	Yes	N/A	Yes	Yes	Yes	Yes
Weber et al ₅₄	Yes	Yes	Yes	Yes	No	No	Yes	Yes	N/A	Yes	Yes	Yes	Yes
Weidner et al ₆₂	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes
Wong et al ³⁹	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Can't tell	Yes	Yes	Yes	Yes

References

1. Veenma DC, de Klein A, Tibboel D. Developmental and genetic aspects of congenital diaphragmatic hernia. *Pediatric pulmonology* 2012;47(6):534-45. doi: 10.1002/ppul.22553 [published Online First: 2012/04/03]
2. Guner YS, Khemani RG, Qureshi FG, et al. Outcome analysis of neonates with congenital diaphragmatic hernia treated with venovenous vs venoarterial extracorporeal membrane oxygenation. *Journal of pediatric surgery* 2009;44(9):1691-701. doi: 10.1016/j.jpedsurg.2009.01.017 [published Online First: 2009/09/09]
3. Harting MT, Lally KP. The Congenital Diaphragmatic Hernia Study Group registry update. *Seminars in fetal & neonatal medicine* 2014;19(6):370-5. doi: 10.1016/j.siny.2014.09.004 [published Online First: 2014/10/13]
4. Lally KP, Lasky RE, Lally PA, et al. Standardized reporting for congenital diaphragmatic hernia--an international consensus. *Journal of pediatric surgery* 2013;48(12):2408-15. doi: 10.1016/j.jpedsurg.2013.08.014 [published Online First: 2013/12/10]
5. Losty PD. Congenital diaphragmatic hernia: where and what is the evidence? *Seminars in pediatric surgery* 2014;23(5):278-82. doi: 10.1053/j.sempedsurg.2014.09.008 [published Online First: 2014/12/03]
6. Peetsold MG, Heij HA, Kneepkens CM, et al. The long-term follow-up of patients with a congenital diaphragmatic hernia: a broad spectrum of morbidity. *Pediatric surgery international* 2009;25(1):1-17. doi: 10.1007/s00383-008-2257-y [published Online First: 2008/10/09]
7. Graziano JN. Cardiac anomalies in patients with congenital diaphragmatic hernia and their prognosis: a report from the Congenital Diaphragmatic Hernia Study Group. *Journal of pediatric surgery* 2005;40(6):1045-9; discussion 49-50. doi: 10.1016/j.jpedsurg.2005.03.025 [published Online First: 2005/07/02]
8. Hautala J, Karstunen E, Ritvanen A, et al. Congenital diaphragmatic hernia with heart defect has a high risk for hypoplastic left heart syndrome and major extra-cardiac malformations: 10-year national cohort from Finland. 2018;97(2):204-11. doi: <https://doi.org/10.1111/aogs.13274>
9. Montalva L, Lauriti G, Zani A. Congenital heart disease associated with congenital diaphragmatic hernia: A systematic review on incidence, prenatal diagnosis, management, and outcome. *Journal of pediatric surgery* 2019;54(5):909-19. doi: 10.1016/j.jpedsurg.2019.01.018 [published Online First: 2019/03/04]
10. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535. doi: 10.1136/bmj.b2535
11. GA Wells BS, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses: The Ottawa Hospital Research Institute; 2021 [Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp accessed 31/05/2021.
12. CASP Cohort Study Checklist: Critical Appraisal Skills Programme; 2019 [Available from: https://caspuk.net/wp-content/uploads/2018/01/CASP-Cohort-Study-Checklist_2018.pdf accessed 10/03/21.
13. Koh JY, Jung E, Goo HW, et al. Functional and structural evaluation in the lungs of children with repaired congenital diaphragmatic hernia. *BMC pediatrics* 2021;21(1):120. doi: 10.1186/s12887-021-02586-3 [published Online First: 2021/03/13]
14. Marven SS, Smith CM, Claxton D, et al. Pulmonary function, exercise performance, and growth in survivors of congenital diaphragmatic hernia. *Archives of Disease in Childhood* 1998;78(2):137-42. doi: 10.1136/adc.78.2.137
15. Trachsel D, Selvadurai H Fau - Bohn D, Bohn D Fau - Langer JC, et al. Long-term pulmonary morbidity in survivors of congenital diaphragmatic hernia. 2005(8755-6863 (Print))

16. Tan JK, Banton G, Minutillo C, et al. Long-term medical and psychosocial outcomes in congenital diaphragmatic hernia survivors. *Arch Dis Child* 2019;104(8):761-67. doi: 10.1136/archdischild-2018-316091 [published Online First: 2019/03/17]
17. Spoel M, Laas R, Gischler SJ, et al. Diagnosis-related deterioration of lung function after extracorporeal membrane oxygenation. *European Respiratory Journal* 2012;40(6):1531. doi: 10.1183/09031936.00189911
18. Peetsold MG, Heij HA, Nagelkerke AF, et al. Pulmonary function and exercise capacity in survivors of congenital diaphragmatic hernia. *Eur Respir J* 2009;34(5):1140-7. doi: 10.1183/09031936.00181408 [published Online First: 2009/03/14]
19. Spoel M, van der Cammen-van Zijp MH, Hop WC, et al. Lung function in young adults with congenital diaphragmatic hernia; a longitudinal evaluation. *Pediatric pulmonology* 2013;48(2):130-7. doi: 10.1002/ppul.22557 [published Online First: 2012/03/28]
20. Ijsselstijn H, Tibboel D, Hop WJ, et al. Long-term pulmonary sequelae in children with congenital diaphragmatic hernia. *American journal of respiratory and critical care medicine* 1997;155(1):174-80. doi: 10.1164/ajrccm.155.1.9001308 [published Online First: 1997/01/01]
21. Laviola M, Zanini A, Priori R, et al. Thoraco-abdominal asymmetry and asynchrony in congenital diaphragmatic hernia. *Pediatr Pulmonol* 2015;50(9):915-24. doi: 10.1002/ppul.23081 [published Online First: 2014/07/24]
22. Spoel M, Marshall H, H IJ, et al. Pulmonary ventilation and micro-structural findings in congenital diaphragmatic hernia. *Pediatr Pulmonol* 2016;51(5):517-24. doi: 10.1002/ppul.23325 [published Online First: 2015/10/10]
23. Gischler SJ, van der Cammen-van Zijp MH, Mazer P, et al. A prospective comparative evaluation of persistent respiratory morbidity in esophageal atresia and congenital diaphragmatic hernia survivors. *Journal of pediatric surgery* 2009;44(9):1683-90. doi: 10.1016/j.jpedsurg.2008.12.019 [published Online First: 2009/09/09]
24. Dao DT, Hayden LP, Buchmiller TL, et al. Longitudinal Analysis of Pulmonary Function in Survivors of Congenital Diaphragmatic Hernia. *The Journal of pediatrics* 2020;216:158-64.e2. doi: 10.1016/j.jpeds.2019.09.072 [published Online First: 2019/11/11]
25. Haliburton B, Mouzaki M, Chiang M, et al. Pulmonary function and nutritional morbidity in children and adolescents with congenital diaphragmatic hernia. *J Pediatr Surg* 2017;52(2):252-56. doi: 10.1016/j.jpedsurg.2016.11.020 [published Online First: 2016/12/04]
26. Stefanutti G, Filippone M, Tommasoni N, et al. Cardiopulmonary anatomy and function in long-term survivors of mild to moderate congenital diaphragmatic hernia. *Journal of pediatric surgery* 2004;39(4):526-31. doi: 10.1016/j.jpedsurg.2003.12.006 [published Online First: 2004/04/06]
27. Bojanić K, Grizelj R, Dilber D, et al. Cardiopulmonary exercise performance is reduced in congenital diaphragmatic hernia survivors. *Pediatric pulmonology* 2016;51(12):1320-29. doi: 10.1002/ppul.23481 [published Online First: 2016/05/27]
28. Turchetta A, Fintini D, Cafiero G, et al. Physical activity, fitness, and dyspnea perception in children with congenital diaphragmatic hernia. *Pediatric pulmonology* 2011;46(10):1000-6. doi: 10.1002/ppul.21471 [published Online First: 2011/04/27]
29. Moawd SA, Azab AR, Ibrahim ZM, et al. Impacts of Respiratory Muscle Training on Respiratory Functions, Maximal Exercise Capacity, Functional Performance, and Quality of Life in School-Aged Children with Postoperative Congenital Diaphragmatic Hernia. *Disease markers* 2020;2020:8829373. doi: 10.1155/2020/8829373 [published Online First: 2020/09/24]
30. Valfrè L, Braguglia A, Conforti A, et al. Long term follow-up in high-risk congenital diaphragmatic hernia survivors: patching the diaphragm affects the outcome. *Journal of pediatric surgery* 2011;46(1):52-56. doi: 10.1016/j.jpedsurg.2010.09.061

31. Abolmaali N, Koch A, Götzelt K, et al. Lung volumes, ventricular function and pulmonary arterial flow in children operated on for left-sided congenital diaphragmatic hernia: long-term results. *European radiology* 2010;20(7):1580-9. doi: 10.1007/s00330-010-1723-9 [published Online First: 2010/02/18]
32. Egan MJ, Husain N, Stines JR, et al. Mid-term differences in right ventricular function in patients with congenital diaphragmatic hernia compared with controls. *World journal of pediatrics : WJP* 2012;8(4):350-4. doi: 10.1007/s12519-012-0380-2 [published Online First: 2012/11/16]
33. Schwartz IP, Bernbaum JC, Rychik J, et al. Pulmonary hypertension in children following extracorporeal membrane oxygenation therapy and repair of congenital diaphragmatic hernia. *Journal of perinatology : official journal of the California Perinatal Association* 1999;19(3):220-6. doi: 10.1038/sj.jp.7200141 [published Online First: 2000/02/24]
34. Garcia AV, Fingeret AL, Thirumoorthi AS, et al. Lung to head ratio in infants with congenital diaphragmatic hernia does not predict long term pulmonary hypertension. *Journal of pediatric surgery* 2013;48(1):154-7. doi: 10.1016/j.jpedsurg.2012.10.031 [published Online First: 2013/01/22]
35. Mesas-Burgos C, Modée A, Öst E, et al. Addressing the causes of late mortality in infants with congenital diaphragmatic hernia. *Journal of pediatric surgery* 2017;52(4):526-29. doi: 10.1016/j.jpedsurg.2016.08.028 [published Online First: 2016/09/15]
36. Rocha G, Azevedo I, Pinto JC, et al. Follow-up of the survivors of congenital diaphragmatic hernia. *Early Hum Dev* 2012;88(4):255-8. doi: 10.1016/j.earlhumdev.2011.08.025 [published Online First: 2011/09/29]
37. Safavi A, Synnes AR, O'Brien K, et al. Multi-institutional follow-up of patients with congenital diaphragmatic hernia reveals severe disability and variations in practice. *Journal of pediatric surgery* 2012;47(5):836-41. doi: 10.1016/j.jpedsurg.2012.01.032 [published Online First: 2012/05/19]
38. Van Meurs KP, Robbins ST, Reed VL, et al. Congenital diaphragmatic hernia: long-term outcome in neonates treated with extracorporeal membrane oxygenation. *The Journal of pediatrics* 1993;122(6):893-9. doi: 10.1016/s0022-3476(09)90013-0 [published Online First: 1993/06/01]
39. Wong M, Reyes J, Lapidus-Krol E, et al. Pulmonary hypertension in congenital diaphragmatic hernia patients: Prognostic markers and long-term outcomes. *J Pediatr Surg* 2018;53(5):918-24. doi: 10.1016/j.jpedsurg.2018.02.015 [published Online First: 2018/03/06]
40. Shieh HF, Wilson JM, Sheils CA, et al. Does the ex utero intrapartum treatment to extracorporeal membrane oxygenation procedure change morbidity outcomes for high-risk congenital diaphragmatic hernia survivors? *Journal of pediatric surgery* 2017;52(1):22-25. doi: 10.1016/j.jpedsurg.2016.10.010
41. Bojanić K, Grizelj R, Vuković J, et al. Health-related quality of life in children and adolescents with congenital diaphragmatic hernia: a cross-sectional study. *Health Qual Life Outcomes* 2018;16(1):50-50. doi: 10.1186/s12955-018-0869-z
42. Koivusalo A, Pakarinen M, Vanamo K, et al. Health-related quality of life in adults after repair of congenital diaphragmatic defects--a questionnaire study. *Journal of pediatric surgery* 2005;40(9):1376-81. doi: 10.1016/j.jpedsurg.2005.05.037 [published Online First: 2005/09/10]
43. Levesque M, Lum Min SA, Morris MI, et al. Asthma Medication Use in Congenital Diaphragmatic Hernia Survivors: A Retrospective Population Level Data Analysis. *European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery [et al] = Zeitschrift für Kinderchirurgie* 2020;30(1):39-44. doi: 10.1055/s-0039-1698767 [published Online First: 2019/11/11]
44. Ali K, Dassios T, Khaliq SA, et al. Outcomes of infants with congenital diaphragmatic hernia by side of defect in the FETO era. *Pediatr Surg Int* 2019;35(7):743-47. doi: 10.1007/s00383-019-04484-3 [published Online First: 2019/05/16]

45. Bojanić K, Woodbury JM, Cavalcante AN, et al. Congenital diaphragmatic hernia: outcomes of neonates treated at Mayo Clinic with and without extracorporeal membrane oxygenation. *Paediatric anaesthesia* 2017;27(3):314-21. doi: 10.1111/pan.13046 [published Online First: 2017/02/18]
46. Cauley RP, Potanos K, Fullington N, et al. Pulmonary support on day of life 30 is a strong predictor of increased 1 and 5-year morbidity in survivors of congenital diaphragmatic hernia. *J Pediatr Surg* 2015;50(5):849-55. doi: 10.1016/j.jpedsurg.2014.12.007 [published Online First: 2015/03/19]
47. Chiu PP, Sauer C, Mihailovic A, et al. The price of success in the management of congenital diaphragmatic hernia: is improved survival accompanied by an increase in long-term morbidity? *J Pediatr Surg* 2006;41(5):888-92. doi: 10.1016/j.jpedsurg.2006.01.026 [published Online First: 2006/05/09]
48. Crankson SJ, Al Jadaan SA, Namshan MA, et al. The immediate and long-term outcomes of newborns with congenital diaphragmatic hernia. *Pediatric surgery international* 2006;22(4):335-40. doi: 10.1007/s00383-006-1643-6 [published Online First: 2006/02/04]
49. Davis PJ, Firmin RK, Manktelow B, et al. Long-term outcome following extracorporeal membrane oxygenation for congenital diaphragmatic hernia: the UK experience. *J Pediatr* 2004;144(3):309-15. doi: 10.1016/j.jpeds.2003.11.031 [published Online First: 2004/03/06]
50. Engle WA, West KW, Hocutt GA, et al. Adult Outcomes After Newborn Respiratory Failure Treated With Extracorporeal Membrane Oxygenation. *Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies* 2017;18(1):73-79. doi: 10.1097/pcc.0000000000001018 [published Online First: 2016/11/05]
51. Kamata S, Usui N, Kamiyama M, et al. Long-term follow-up of patients with high-risk congenital diaphragmatic hernia. *J Pediatr Surg* 2005;40(12):1833-8. doi: 10.1016/j.jpedsurg.2005.08.022 [published Online First: 2005/12/13]
52. Morsberger JL, Short HL, Baxter KJ, et al. Parent reported long-term quality of life outcomes in children after congenital diaphragmatic hernia repair. *Journal of pediatric surgery* 2019;54(4):645-50. doi: 10.1016/j.jpedsurg.2018.06.009 [published Online First: 2018/07/05]
53. Pal K, Gupta DK. Serial perfusion study depicts pulmonary vascular growth in the survivors of non-extracorporeal membrane oxygenation-treated congenital diaphragmatic hernia. *Neonatology* 2010;98(3):254-9. doi: 10.1159/000278820 [published Online First: 2010/04/24]
54. Weber TR, Tracy T, Jr., Bailey PV, et al. Congenital diaphragmatic hernia beyond infancy. *American journal of surgery* 1991;162(6):643-6. doi: 10.1016/0002-9610(91)90127-y [published Online First: 1991/12/11]
55. Trachsel D, Selvadurai H, Adatia I, et al. Resting and exercise cardiorespiratory function in survivors of congenital diaphragmatic hernia. *Pediatric pulmonology* 2006;41(6):522-9. doi: 10.1002/ppul.20359 [published Online First: 2006/04/18]
56. Zaccara A, Turchetta A, Calzolari A, et al. Maximal oxygen consumption and stress performance in children operated on for congenital diaphragmatic hernia. *Journal of pediatric surgery* 1996;31(8):1092-4; discussion 95. doi: 10.1016/s0022-3468(96)90094-9 [published Online First: 1996/08/01]
57. Peetsold MG, Vonk-Noordegraaf A, Heij HH, et al. Pulmonary function and exercise testing in adult survivors of congenital diaphragmatic hernia. *Pediatr Pulmonol* 2007;42(4):325-31. doi: 10.1002/ppul.20579 [published Online First: 2007/03/16]
58. Toussaint-Duyster LCC, van der Cammen-van Zijp MHM, de Jongste JC, et al. Congenital diaphragmatic hernia and exercise capacity, a longitudinal evaluation. *Pediatric pulmonology* 2019;54(5):628-36. doi: 10.1002/ppul.24264 [published Online First: 2019/02/12]

59. Kamata S, Usui N, Sawai T, et al. Radiographic changes in the diaphragm after repair of congenital diaphragmatic hernia. *J Pediatr Surg* 2008;43(12):2156-60. doi: 10.1016/j.jpedsurg.2008.08.042 [published Online First: 2008/12/02]
60. Arena F, Baldari S, Centorrino A, et al. Mid- and long-term effects on pulmonary perfusion, anatomy and diaphragmatic motility in survivors of congenital diaphragmatic hernia. *Pediatric surgery international* 2005;21(12):954-59. doi: 10.1007/s00383-005-1557-8
61. Khirani S, Amaddeo A, Khen-Dunlop N, et al. Diaphragmatic function in infants and children with congenital diaphragmatic hernia: A cross-sectional study. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* 2017;53 doi: 10.1093/ejcts/ezx391
62. Weidner M, Zöllner FG, Hagelstein C, et al. High temporal versus high spatial resolution in MR quantitative pulmonary perfusion imaging of two-year old children after congenital diaphragmatic hernia repair. *European radiology* 2014;24(10):2427-34. doi: 10.1007/s00330-014-3304-9 [published Online First: 2014/07/21]
63. Stoll-Dannenhauer T, Schwab G, Zahn K, et al. Computed tomography based measurements to evaluate lung density and lung growth after congenital diaphragmatic hernia. *Scientific reports* 2021;11(1):5035. doi: 10.1038/s41598-021-84623-w [published Online First: 2021/03/05]
64. Hayward MJ, Kharasch V, Sheils C, et al. Predicting inadequate long-term lung development in children with congenital diaphragmatic hernia: an analysis of longitudinal changes in ventilation and perfusion. *J Pediatr Surg* 2007;42(1):112-6. doi: 10.1016/j.jpedsurg.2006.09.011 [published Online First: 2007/01/09]
65. King SK, Alfaraj M, Gaiteiro R, et al. Congenital diaphragmatic hernia: Observed/expected lung-to-head ratio as a predictor of long-term morbidity. *Journal of pediatric surgery* 2016;51(5):699-702. doi: 10.1016/j.jpedsurg.2016.02.004 [published Online First: 2016/03/05]
66. Muratore CS, Kharasch V, Lund DP, et al. Pulmonary morbidity in 100 survivors of congenital diaphragmatic hernia monitored in a multidisciplinary clinic. *Journal of pediatric surgery* 2001;36(1):133-40. doi: 10.1053/jpsu.2001.20031 [published Online First: 2001/01/11]
67. Michel F, Baumstarck K, Gosselin A, et al. Health-related quality of life and its determinants in children with a congenital diaphragmatic hernia. *Orphanet J Rare Dis* 2013;8:89. doi: 10.1186/1750-1172-8-89 [published Online First: 2013/06/22]
68. Poley MJ, Stolk EA, Tibboel D, et al. Short term and long term health related quality of life after congenital anorectal malformations and congenital diaphragmatic hernia. *Arch Dis Child* 2004;89(9):836-41. doi: 10.1136/adc.2002.016543 [published Online First: 2004/08/24]
69. Amin R, Knezevich M, Lingongo M, et al. Long-term Quality of Life in Neonatal Surgical Disease. *Annals of surgery* 2018;268(3):497-505. doi: 10.1097/SLA.0000000000002918
70. Chen C, Jeruss S, Chapman JS, et al. Long-term functional impact of congenital diaphragmatic hernia repair on children. *Journal of pediatric surgery* 2007;42(4):657-65. doi: 10.1016/j.jpedsurg.2006.12.013 [published Online First: 2007/04/24]
71. Fritz KA, Khmour AY, Kitzerow K, et al. Health-related quality of life, educational and family outcomes in survivors of congenital diaphragmatic hernia. *Pediatric surgery international* 2019;35(3):315-20. doi: 10.1007/s00383-018-4414-2
72. Öst E, Frenckner B, Nisell M, et al. Health-related quality of life in children born with congenital diaphragmatic hernia. *Pediatric surgery international* 2018;34(4):405-14. doi: 10.1007/s00383-018-4237-1 [published Online First: 2018/02/18]
73. Peetsold MG, Huisman J, Hofman VE, et al. Psychological outcome and quality of life in children born with congenital diaphragmatic hernia. *Arch Dis Child* 2009;94(11):834-40. doi: 10.1136/adc.2008.156158 [published Online First: 2009/06/18]
74. Sheikh F, Akinkuotu A, Clark SJ, et al. Assessment of quality of life outcomes using the pediatric quality of life inventory survey in prenatally diagnosed congenital diaphragmatic hernia

- patients. *Journal of pediatric surgery* 2016;51(4):545-8. doi: 10.1016/j.jpedsurg.2015.11.006 [published Online First: 2015/12/26]
75. Fritz KA, Khmour AY, Kitzerow K, et al. Health-related quality of life, educational and family outcomes in survivors of congenital diaphragmatic hernia. *Pediatric surgery international* 2019;35(3):315-20. doi: 10.1007/s00383-018-4414-2 [published Online First: 2018/11/13]
 76. Amin R, Knezevich M, Lingongo M, et al. Long-term Quality of Life in Neonatal Surgical Disease. *Annals of surgery* 2018;268(3):497-505. doi: 10.1097/sla.0000000000002918 [published Online First: 2018/07/12]
 77. Respiratory Diseases of the Newborn Infant 2021.
 78. McGeachie MJ, Yates KP, Zhou X, et al. Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. 2016;374(19):1842-52. doi: 10.1056/NEJMoa1513737
 79. Iacusso C, Morini F, Capolupo I, et al. Lung Transplantation for Late-Onset Pulmonary Hypertension in a Patient with Congenital Diaphragmatic Hernia. *European J Pediatr Surg Rep* 2018;6(1):e100-e03. doi: 10.1055/s-0038-1675377 [published Online First: 2018/12/26]
 80. Morini F, Valfrè L, Capolupo I, et al. Congenital diaphragmatic hernia: defect size correlates with developmental defect. *Journal of pediatric surgery* 2013;48(6):1177-82. doi: 10.1016/j.jpedsurg.2013.03.011 [published Online First: 2013/07/13]
 81. Tan YW, Ali K, Andradi G, et al. Prognostic value of the oxygenation index to predict survival and timing of surgery in infants with congenital diaphragmatic hernia. *Journal of pediatric surgery* 2019;54(8):1567-72. doi: 10.1016/j.jpedsurg.2018.11.014 [published Online First: 2019/01/27]
 82. Nystad W, Samuelsen SO, Nafstad P, et al. Feasibility of measuring lung function in preschool children. 2002;57(12):1021-27. doi: 10.1136/thorax.57.12.1021
 83. Gaffin JM, Shotola NL, Martin TR, et al. Clinically useful spirometry in preschool-aged children: evaluation of the 2007 American Thoracic Society Guidelines. *J Asthma* 2010;47(7):762-67. doi: 10.3109/02770903.2010.485664
 84. Hollinger LE, Harting MT, Lally KP. Long-term follow-up of congenital diaphragmatic hernia. *Seminars in pediatric surgery* 2017;26(3):178-84. doi: 10.1053/j.sempedsurg.2017.04.007 [published Online First: 2017/06/24]
 85. Delacourt C, Hadchouel A, Toelen J, et al. Long term respiratory outcomes of congenital diaphragmatic hernia, esophageal atresia, and cardiovascular anomalies. *Seminars in Fetal and Neonatal Medicine* 2012;17(2):105-11. doi: <https://doi.org/10.1016/j.siny.2012.01.008>
 86. Bagolan P, Morini F. Long-term follow up of infants with congenital diaphragmatic hernia. *Semin Pediatr Surg* 2007;16(2):134-44. doi: 10.1053/j.sempedsurg.2007.01.009 [published Online First: 2007/04/28]
 87. Ijsselstijn H, van Heijst AF. Long-term outcome of children treated with neonatal extracorporeal membrane oxygenation: increasing problems with increasing age. *Semin Perinatol* 2014;38(2):114-21. doi: 10.1053/j.semperi.2013.11.009 [published Online First: 2014/03/04]
 88. Leeuwen L, Fitzgerald DA. Congenital diaphragmatic hernia. *Journal of paediatrics and child health* 2014;50(9):667-73. doi: 10.1111/jpc.12508 [published Online First: 2014/02/18]
 89. Matina F, Piro E, Zicari C, et al. Congenital diaphragmatic hernia and esophageal atresia: The importance of respiratory follow-up in congenital thoracic malformations. *Acta Medica Mediterranea* 2013;29(2):343-47.
 90. Morini F, Valfrè L, Bagolan P. Long-term morbidity of congenital diaphragmatic hernia: A plea for standardization. *Semin Pediatr Surg* 2017;26(5):301-10. doi: 10.1053/j.sempedsurg.2017.09.002 [published Online First: 2017/11/08]
 91. van den Hout L, Sluiter I, Gischler S, et al. Can we improve outcome of congenital diaphragmatic hernia? *Pediatric surgery international* 2009;25(9):733-43. doi: 10.1007/s00383-009-2425-8 [published Online First: 2009/08/12]
 92. West SD, Wilson JM. Follow Up of Infants with Congenital Diaphragmatic Hernia. *Seminars in perinatology* 2005;29(2):129-33. doi: <https://doi.org/10.1053/j.semperi.2005.04.007>

93. Losty PD. Congenital Diaphragmatic Hernia and Eventration. In: Losty PD, Flake AW, Rintala RJ, et al., eds. *Rickham's Neonatal Surgery*. London: Springer London 2018:595-604.
94. Turchetta A, Fintini D, Cafiero G, et al. Physical activity, fitness, and dyspnea perception in children with congenital diaphragmatic hernia. *Pediatric pulmonology* 2011;46(10):1000-06. doi: 10.1002/ppul.21471
95. Majaesic CM, Jones R, Dinu IA, et al. Clinical correlations and pulmonary function at 8 years of age after severe neonatal respiratory failure. 2007;42(9):829-37. doi: <https://doi.org/10.1002/ppul.20663>
96. Moawd SA, Azab AR, Ibrahim ZM, et al. Impacts of Respiratory Muscle Training on Respiratory Functions, Maximal Exercise Capacity, Functional Performance, and Quality of Life in School-Aged Children with Postoperative Congenital Diaphragmatic Hernia. *Disease markers* 2020;2020 doi: 10.1155/2020/8829373
97. Cashen K, Reeder RW, Shanti C, et al. Is therapeutic hypothermia during neonatal extracorporeal membrane oxygenation associated with intracranial hemorrhage? *Perfusion* 2018;33(5):354-62. doi: 10.1177/0267659117747693 [published Online First: 2017/12/11]
98. Chiu P, Hedrick HL. Postnatal management and long-term outcome for survivors with congenital diaphragmatic hernia. *Prenatal diagnosis* 2008;28(7):592-603. doi: 10.1002/pd.2007 [published Online First: 2008/06/14]
99. Cortes RA, Keller RL, Townsend T, et al. Survival of severe congenital diaphragmatic hernia has morbid consequences. *Journal of pediatric surgery* 2005;40(1):36-45; discussion 45-6. doi: 10.1016/j.jpedsurg.2004.09.037 [published Online First: 2005/05/04]
100. Glinianaia SV, Morris JK, Best KE, et al. Long-term survival of children born with congenital anomalies: A systematic review and meta-analysis of population-based studies. *PLOS Medicine* 2020;17(9):e1003356. doi: 10.1371/journal.pmed.1003356
101. Hamutcu R, Nield TA, Garg M, et al. Long-term pulmonary sequelae in children who were treated with extracorporeal membrane oxygenation for neonatal respiratory failure. *Pediatrics* 2004;114(5):1292-6. doi: 10.1542/peds.2003-1080-L [published Online First: 2004/11/03]
102. Hollinger LE, Buchmiller TL. Long term follow-up in congenital diaphragmatic hernia. *Semin Perinatol* 2020;44(1):151171. doi: 10.1053/j.semperi.2019.07.010 [published Online First: 2019/08/28]
103. Huddy CLJ, Boyd PA, Wilkinson AR, et al. Congenital diaphragmatic hernia: prenatal diagnosis, outcome and continuing morbidity in survivors. 1999;106(11):1192-96. doi: <https://doi.org/10.1111/j.1471-0528.1999.tb08147.x>
104. Iguchi A, Ridout DA, Galan S, et al. Long-term survival outcomes and causes of late death in neonates, infants, and children treated with extracorporeal life support. *Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies* 2013;14(6):580-6. doi: 10.1097/PCC.0b013e3182917a81 [published Online First: 2013/07/05]
105. H IJ, Breatnach C, Hoskote A, et al. Defining outcomes following congenital diaphragmatic hernia using standardised clinical assessment and management plan (SCAMP) methodology within the CDH EURO consortium. *Pediatric research* 2018;84(2):181-89. doi: 10.1038/s41390-018-0063-3 [published Online First: 2018/06/20]
106. Kassner N, Weis M, Zahn K, et al. Histogram based analysis of lung perfusion of children after congenital diaphragmatic hernia repair. *Magnetic resonance imaging* 2018;48:42-49. doi: 10.1016/j.mri.2017.11.013 [published Online First: 2017/11/28]
107. Kattan M. Long-Term Sequelae of Respiratory Illness in Infancy and Childhood. *Pediatric Clinics of North America* 1979;26(3):525-35. doi: [https://doi.org/10.1016/S0031-3955\(16\)33747-6](https://doi.org/10.1016/S0031-3955(16)33747-6)
108. Lally KP, Engle W. Postdischarge follow-up of infants with congenital diaphragmatic hernia. *Pediatrics* 2008;121(3):627-32. doi: 10.1542/peds.2007-3282 [published Online First: 2008/03/04]

109. Leeuwen L, Fitzgerald DA. Congenital diaphragmatic hernia. 2014;50(9):667-73. doi: <https://doi.org/10.1111/jpc.12508>
110. Lund DP, Mitchell J, Kharasch V, et al. Congenital diaphragmatic hernia: the hidden morbidity. *Journal of pediatric surgery* 1994;29(2):258-62; discussion 62-4. doi: 10.1016/0022-3468(94)90329-8 [published Online First: 1994/02/01]
111. Mansell AL. Survivors of neonatal congenital lung diseases: pulmonary follow-up. *Pediatric pulmonology Supplement* 1997;16:252-3. doi: 10.1002/ppul.19502308130 [published Online First: 1997/01/01]
112. Mota R, Rocha G, Flor-de-Lima F, et al. Persistent pulmonary hypertension – The neonatal period and evaluation at 2 years of age. *Journal of Pediatric and Neonatal Individualized Medicine (JPNIM)* 2016;5(1):e050119. doi: 10.7363/050119
113. Mugford M, Elbourne D, Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. *The Cochrane database of systematic reviews* 2008(3):Cd001340. doi: 10.1002/14651858.CD001340.pub2 [published Online First: 2008/07/23]
114. Nobuhara KK, Lund DP, Mitchell J, et al. Long-term outlook for survivors of congenital diaphragmatic hernia. *Clin Perinatol* 1996;23(4):873-87. [published Online First: 1996/12/01]
115. Prendergast M, Rafferty GF, Milner AD, et al. Lung function at follow-up of infants with surgically correctable anomalies. *Pediatric pulmonology* 2012;47(10):973-8. doi: 10.1002/ppul.22515 [published Online First: 2012/02/14]
116. Suda K, Bigras JL, Bohn D, et al. Echocardiographic predictors of outcome in newborns with congenital diaphragmatic hernia. *Pediatrics* 2000;105(5):1106-9. doi: 10.1542/peds.105.5.1106 [published Online First: 2000/05/03]
117. Weaver KL, Baerg JE, Okawada M, et al. A multi-institutional review of thoracoscopic congenital diaphragmatic hernia repair. *Journal of Laparoendoscopic and Advanced Surgical Techniques* 2016;26(10):825-30. doi: 10.1089/lap.2016.0358
118. van der Cammen-van Zijp MH, Spoel M, Laas R, et al. Exercise capacity, daily activity, and severity of fatigue in term born young adults after neonatal respiratory failure. *Scandinavian journal of medicine & science in sports* 2014;24(1):144-51. doi: 10.1111/j.1600-0838.2012.01491.x [published Online First: 2012/06/26]
119. van der Cammen-van Zijp MH, Gischler SJ, Hop WC, et al. Deterioration of exercise capacity after neonatal extracorporeal membrane oxygenation. *The European respiratory journal* 2011;38(5):1098-104. doi: 10.1183/09031936.00076410 [published Online First: 2011/05/05]
120. Vanamo K, Rintala R, Sovijärvi A, et al. Long-term pulmonary sequelae in survivors of congenital diaphragmatic defects. *Journal of pediatric surgery* 1996;31(8):1096-100. doi: 10.1016/S0022-3468(96)90095-0
121. Zach MS, Eber E. Adult outcome of congenital lower respiratory tract malformations. *Thorax* 2001;56(1):65-72. doi: 10.1136/thorax.56.1.65 [published Online First: 2000/12/20]
122. Zöllner FG, Zahn K, Schaible T, et al. Quantitative pulmonary perfusion imaging at 3.0 T of 2-year-old children after congenital diaphragmatic hernia repair: initial results. *European radiology* 2012;22(12):2743-9. doi: 10.1007/s00330-012-2528-9 [published Online First: 2012/06/14]
123. Ferrante G, Cilluffo G, Di Pace MR, et al. New insights in respiratory impedance in young children after repair of congenital diaphragmatic hernia: a cross-sectional study. *Italian journal of pediatrics* 2019;45(1):82. doi: 10.1186/s13052-019-0670-6
124. Gray BW, Fifer CG, Hirsch JC, et al. Contemporary outcomes in infants with congenital heart disease and bochdalek diaphragmatic hernia. 2013;95 3:929-34.

